1.
2.
EBV strain interacts with host HLA to drive nasopharyngeal carcinoma risk
(feeds.nature.com)
3.
Risk-adaptive therapy guided by dynamic ctDNA in nasopharyngeal carcinoma
(feeds.nature.com)